| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... New England Journal of Medicine 369 (6), 507-516, 2013 | 1964 | 2013 |
| Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ... Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998 | 1300 | 1998 |
| Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ... Journal of Clinical Oncology 35 (19), 2125-2132, 2017 | 1060 | 2017 |
| Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ... New England Journal of Medicine 374 (25), 2419-2429, 2016 | 868 | 2016 |
| Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ... New England Journal of Medicine 372 (17), 1598-1607, 2015 | 830 | 2015 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 825 | 2018 |
| Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of … D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ... The Lancet 381 (9880), 1817-1826, 2013 | 680 | 2013 |
| European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma … JM Foran, AZS Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ... Journal of Clinical Oncology 18 (2), 317-317, 2000 | 600 | 2000 |
| Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial R Pettengell, H Gurney, JA Radford, DP Deakin, R James, PM Wilkinson, ... | 555 | 1992 |
| Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ... Journal of Clinical Oncology 26 (32), 5156-5164, 2008 | 541 | 2008 |
| Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study AJ Swerdlow, CD Higgins, P Smith, D Cunningham, BW Hancock, ... Journal of the National Cancer Institute 99 (3), 206-214, 2007 | 535 | 2007 |
| Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial A Le Cesne, JY Blay, I Judson, A Van Oosterom, J Verweij, J Radford, ... Journal of Clinical Oncology 23 (3), 576-584, 2005 | 530 | 2005 |
| Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are … J Verweij, A van Oosterom, JY Blay, I Judson, S Rodenhuis, ... European Journal of Cancer 39 (14), 2006-2011, 2003 | 518 | 2003 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 513 | 2020 |
| Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015 | 485 | 2015 |
| Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the … I Judson, JA Radford, M Harris, JY Blay, Q van Hoesel, A Le Cesne, ... European Journal of Cancer 37 (7), 870-877, 2001 | 460 | 2001 |
| Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma JA Radford, BA Lieberman, DR Brison, ARB Smith, JD Critchlow, ... The Lancet 357 (9263), 1172-1175, 2001 | 459 | 2001 |
| Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas JM Vose, RL Wahl, M Saleh, AZ Rohatiner, SJ Knox, JA Radford, ... Journal of clinical oncology 18 (6), 1316-1323, 2000 | 439 | 2000 |
| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ... The Lancet Oncology 22 (6), 790-800, 2021 | 420 | 2021 |
| How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? HG Laverty, C Benson, EJ Cartwright, MJ Cross, C Garland, T Hammond, ... British journal of pharmacology 163 (4), 675-693, 2011 | 409 | 2011 |
